INCAGN01949, a fully human IgG1 anti-OX40 agonist mAb, was developed to boost tumor-specific immunity by activating effector T cells and depleting Tregs through Fcγ receptor engagement. This evidence concerns the gene TNFRSF4 and neoplasm.